Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Court Upholds Patent For Plavix
June 25, 2007
| A version of this story appeared in
Volume 85, Issue 26
The U.S. District Court for the Southern District of New York has upheld the validity of Sanofi-Aventis' patent for the blood thinner Plavix, which Sanofi and Bristol-Myers Squibb jointly market in the U.S. The court also ruled that Canadian generic drugmaker Apotex infringed the patent. Exploiting loopholes in a deal with BMS, Apotex launched its version of the drug in August 2006, hurting profits at the two big firms and prompting the ouster of BMS CEO Peter R. Dolan. The judge hearing the case plans to schedule a session to determine the damages Apotex will have to pay.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter